Abstract
Retinoic acid receptor beta 2 (RARβ2) isoform has been considered a putative tumor suppressor because it is expressed in normal cells but is lacking in most tumors, including breast cancer. Recently, we identified a novel RARβ isoform (β5) in breast cancer cells, which may sereve as a potential target of retinoids in cancer prevention and therapy studies. In this review are summarized the data on the expression of RARβ5 and of the previously identified RARβ4 and RARβ isoforms in various breast cancer cell lines. We found that RARβ5 may serve as a potential biomarker of resistance of breast cancer cells to retinoids and thus may have clinical implication in selecting patients that may benefit the most from clinical trials with retinoids.
Keywords: Retinoids, retinoid receptors, RARβ5 isoform, breast cancer, prevention
Current Cancer Drug Targets
Title: The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Volume: 9 Issue: 2
Author(s): Konstantin Christov
Affiliation:
Keywords: Retinoids, retinoid receptors, RARβ5 isoform, breast cancer, prevention
Abstract: Retinoic acid receptor beta 2 (RARβ2) isoform has been considered a putative tumor suppressor because it is expressed in normal cells but is lacking in most tumors, including breast cancer. Recently, we identified a novel RARβ isoform (β5) in breast cancer cells, which may sereve as a potential target of retinoids in cancer prevention and therapy studies. In this review are summarized the data on the expression of RARβ5 and of the previously identified RARβ4 and RARβ isoforms in various breast cancer cell lines. We found that RARβ5 may serve as a potential biomarker of resistance of breast cancer cells to retinoids and thus may have clinical implication in selecting patients that may benefit the most from clinical trials with retinoids.
Export Options
About this article
Cite this article as:
Christov Konstantin, The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer, Current Cancer Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/156800909787580953
DOI https://dx.doi.org/10.2174/156800909787580953 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Current Cancer Drug Targets Editorial
Current Medical Imaging Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design (6-Bromo-1,4-dimethyl-9<i>H</i>-carbazol-3-yl-methylene)-hydrazine (Carbhydraz) Acts as a GPER Agonist in Breast Cancer Cells
Current Topics in Medicinal Chemistry Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics The Salivary miRNome: A Promising Biomarker of Disease
MicroRNA Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets
Mini-Reviews in Medicinal Chemistry Core-shell Semiconductor Nanocrystals: Effect of Composition, Size, Surface Coatings on their Optical Properties, Toxicity and Pharmacokinetics
Current Pharmaceutical Design Menopausal Transition and Chronic Diseases
Current Women`s Health Reviews Facile Synthesis of Bis(indolyl)alkanes Catalyzed by Cu(ClO4)2.6H2O Under Solvent Free Conditions
Letters in Organic Chemistry Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics
Current Signal Transduction Therapy IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism